Icodec was found to perform equally in insulin-naïve and insulin-treated T2D individuals, indicating that baseline antihyperglycemic treatment does not affect the clinical response to Icodec when stated de novo or switched from another basal analog [49]. This evidence concerns the gene INS and type 2 diabetes mellitus.